Plain-English translation of NCT07160179 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing an investigational medication called as a treatment for geographic atrophy, which is an advanced form of age-related macular degeneration—a condition that causes progressive vision loss in the center of your sight. The medication is given as an injection directly into the eye. The study will help researchers understand whether this treatment is safe and whether it can help slow or stop vision loss.
Geographic atrophy is a serious condition that currently has very limited treatment options. This medication works differently from approved treatments, and researchers want to find out if it could offer patients a new way to protect their remaining vision.
You likely qualify if…
You likely don't qualify if…
You would visit a clinic weekly during the study period to receive injections of the medication into your eye and undergo regular eye exams and blood tests. The study has two stages: in Stage 1, different groups receive different single or repeated doses to test safety; in Stage 2, some participants receive the new medication while others receive an already-approved treatment for comparison. The entire commitment is approximately 25 months, including treatment and follow-up.
AI-generated summary from trial data · Jun 21, 2026 · Not medical advice
United States